A Case of Graves’ Disease Following Vaccination with the Oxford-AstraZeneca SARS-CoV-2 Vaccine: Case Report and Review of the Literature

Dalia Cuenca; Mercedes Aguilar-Soto; Moises Mercado

doi:10.12890/2022_003275

Dalia Cuenca
Department of Endocrinology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico https://orcid.org/0000-0001-9961-4667
Mercedes Aguilar-Soto
Department of Internal Medicine, American British Cowdray Medical Center, Mexico City, Mexico https://orcid.org/0000-0002-3522-8406
Moises Mercado
Endocrine Research Unit, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico https://orcid.org/0000-0002-4748-9734

Keywords

Graves' disease, AstraZeneca, COVID-19

Abstract

A 57-year-old man presented to the outpatient clinic with tremor, palpitations, weight loss and fatigue 1 week after receiving the first dose of the Oxford-AstraZeneca SARS-CoV-2 vaccine (ChAdOx1 nCoV-19). Laboratory studies showed a suppressed TSH with elevated total and free T4. Thyroid peroxidase and thyroglobulin antibodies were elevated but thyrotropin receptor autoantibodies were indeterminate. Thyroid scintigraphy with technetium Tc-99m pertechnetate revealed increased diffuse, symmetric uptake. The patient was treated with thiamazole 15 mg three times a day and propranolol with resolution of his symptoms and normalization of his thyroid function tests until discontinuation of the antithyroid drug 6 months after symptom onset.

VIEW THE ENTIRE ARTICLE

HTML
PDF

References

WHO. Weekly epidemiological update on COVID-19 - April 7th 2022. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports (accessed April 7 2022)

Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol 2021;33(2):155–162. doi:10.1097/BOR.0000000000000776

Pujol A, Gómez LA, Gallegos C, Nicolau J, Sanchís P, González-Freire M, et al. Thyroid as a target of adjuvant autoimmunity/inflammatory syndrome due to mRNA-based SARS-CoV2 vaccination: from Graves' disease to silent thyroiditis. J Endocrinol Invest 2022 Apr;45(4):875–882. doi:10.1007/s40618-021-01707-0

Chen Y, Xu Z, Wang P, Li XM, Shuai ZW, Ye DQ, et al. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology 2022 Apr;165(4):386–401. doi:10.1111/imm.13443

Vera-Lastra O, Ordinola Navarro A, Cruz Domiguez MP, Medina G, Sánchez Valadez TI, Jara LJ. Two cases of Graves' disease following SARS-CoV-2 vaccination: an autoimmune/inflammatory syndrome induced by adjuvants. Thyroid 2021;31(9):1436–1439. doi:10.1089/thy.2021.0142

Zettinig G, Krebs M. Two further cases of Graves' disease following SARS-Cov-2 vaccination. J Endocrinol Invest 2022;45(1):227–228. doi:10.1007/s40618-021-01650-0

Hamouche W, El Soufi Y, Alzaraq S, Okafor BV, Zhang F, Paras C. A case report of new onset graves' disease induced by SARS-CoV-2 infection or vaccine?. J Clin Transl Endocrinol Case Rep 2022;23:100104. doi:10.1016/j.jecr.2021.100104

Pla Peris B, Merchante Alfaro AÁ, Maravall Royo FJ, Abellán Galiana P, Pérez Naranjo S, González Boillos M. Thyrotoxicosis following SARS-COV-2 vaccination: a case series and discussion.J Endocrinol Invest 2022 Jan 11;1–7. doi:10.1007/s40618-022-01739-0. Online ahead of print.

Weintraub MA, Ameer B, Sinha Gregory N. Graves disease following the SARS-CoV-2 vaccine: case series. J Investig Med High Impact Case Rep 2021;9:23247096211063356. doi:10.1177/23247096211063356

Patrizio A, Ferrari SM, Antonelli A, Fallahi P. A case of Graves' disease and type 1 diabetes mellitus following SARS-CoV-2 vaccination. J Autoimmun 2021;125:102738. doi:10.1016/j.jaut.2021.102738

Sriphrapradang C, Shantavasinkul PC. Graves' disease following SARS-CoV-2 vaccination. Endocrine 2021;74(3):473–474. doi:10.1007/s12020-021-02902-y

Lui DTW, Lee KK, Lee CH, Lee ACH, Hung IFN, Tan KCB. Development of Graves' disease after SARS-CoV-2 mRNA vaccination: a case report and literature review. Front Public Health 2021;9:778964. doi:10.3389/fpubh.2021.778964

Rubinstein TJ. Thyroid eye disease following COVID-19 vaccine in a patient with a history Graves' disease: a case report. Ophthalmic Plast Reconstr Surg 2021;37(6):e221–e223. doi:10.1097/IOP.0000000000002059

Goblirsch TJ, Paulson AE, Tashko G, Mekonnen AJ. Graves' disease following administration of second dose of SARS-CoV-2 vaccine. BMJ Case Rep 2021;14(12):e246432. doi:10.1136/bcr-2021-246432

Pierman G, Delgrange E, Jonas C. Recurrence of Graves' disease (a Th1-type cytokine disease) following SARS-CoV-2 mRNA vaccine administration: a simple coincidence?. Eur J Case Rep Intern Med 2021;8(9):002807. doi:10.12890/2021_002807

Sriphrapradang C. Aggravation of hyperthyroidism after heterologous prime-boost immunization with inactivated and adenovirus-vectored SARS-CoV-2 vaccine in a patient with Graves' disease. Endocrine 2021;74(2):226–227. doi:10.1007/s12020-021-02879-8

Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front Immunol 2021 Jan 19;11:617089. doi:10.3389/fimmu.2020.617089

Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol 2021;21(4):195–197. doi:10.1038/s41577-021-005

HTML
PDF

Views: 730
HTML downloads: 951
PDF downloads: 477

Published: 2022-04-14
Issue: 2022: Vol 9 No 4 (view)

How to cite:

1.

Cuenca D, Aguilar-Soto M, Mercado M. A Case of Graves’ Disease Following Vaccination with the Oxford-AstraZeneca SARS-CoV-2 Vaccine: Case Report and Review of the Literature. EJCRIM 2022;9 doi:10.12890/2022_003275.

Similar Articles